Yi-Jong Lin

Consigliere Generale presso TaiGen Biotechnology Co., Ltd.

Consumer Non-Durables

Consumer Services

Health Technology

Profilo

Yi-Jong Lin is a professional who currently holds the position of Vice President-Regulatory Affairs at TaiGen Biotechnology Co., Ltd.
Prior to this, he worked as a Principal at Colgate-Palmolive Co. and Eisai Medical Research, Inc. Dr. Lin received his graduate and doctorate degrees from the University of Tokyo.

Posizioni attive di Yi-Jong Lin

Società	Posizione	Inizio
TaiGen Biotechnology Co., Ltd. TaiGen Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.	Consigliere Generale	11/01/2010

Tutte le posizioni attive di Yi-Jong Lin

Precedenti posizioni note di Yi-Jong Lin

Società	Posizione	Fine
COLGATE-PALMOLIVE COMPANY	Corporate Officer/Principal	-
Eisai Medical Research, Inc.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Yi-Jong Lin

Formazione di Yi-Jong Lin

University of Tokyo

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Yi-Jong Lin

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
COLGATE-PALMOLIVE COMPANY	Consumer Non-Durables

Aziende private	2
TaiGen Biotechnology Co., Ltd. TaiGen Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.	Health Technology
Eisai Medical Research, Inc.